Latest news for Innoviva (NASDAQ:INVA) Stock

Innoviva

Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.

Businessman.Market.Ahead.Shutterstock

Analyst Color

Biotech

Equities

News

Health Care

Initiation

Analyst Ratings

Trading Ideas

General

INVA

Discover Cantor Fitzgerald&#39;s analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products.

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

Small Cap

Movers

AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter

Long Ideas

Insider Trades

Pre-Market Outlook

Markets

DISH

MGTX

Although US stocks closed higher on Monday, there were a few notable insider trades.

Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying

Innoviva Inc

Invacare Corp

FHLC: Healthcare Dashboard For July

Top 5 Value Stocks For A Big Tech Pullback (SA Quant)

Innoviva ($INVA), a thriving biotech stock, has captured investors' attention as the shares have shot up over 36% in the past year. Its success is ...

Innoviva's (INVA) Stock Is Thriving With Strategic Investments Pay-Off

The biotech industry shows promise due to advanced trends like AI and VR simulations, a growing global patient population, and increased R&D spending in 2024. Therefore, let's analyze the fundamentals of biotech stocks, Innoviva (INVA) and Entrada Therapeutics (TRDA) to understand why they are worth watching this month. Read more... The biotech sector is experiencing strong growth due to continuous innovation and a focus on unmet healthcare needs. Rising global demand for quality care, personalized treatments, and advanced technology fuels this expansion. Notably, biotech firms specializing in precision oncology and AI-driven drug development offer promising investment opportunities.
Amid this favorable backdrop, investors might consider adding promising biotech stocks like Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>) and Entrada Therapeutics, Inc. (<a href="https://stocknews.com/stock/TRDA/">TRDA</a>) to their watchlist this month.
This year, investment in immunology and inflammation is surging due to scientific advances and a growing global patient population. New drugs are targeting previously unreachable pathways, providing broad treatment potential and high revenue prospects. Consequently, the global biotechnology market is projected to reach $3.88 trillion by 2030, with a <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">14% CAGR</a>.
Despite <a href="https://www.rttnews.com/3463509/biotech-stocks-facing-fda-decision-in-august-2024.aspx?refresh=1">fewer drug approvals</a> this year compared to last, the biotech sector is expanding rapidly. This growth is driven by increased R&amp;D investments, particularly in AI and advanced platforms for drug development. The focus on treating rare diseases and creating innovative vaccines and therapies makes the sector promising and poised for future success.
On top of it, advances in AI and machine learning are transforming biotech by speeding up drug discovery and development, supporting personalized medicine, and improving synthetic biology and diagnostics. These technologies make drug development faster and more affordable. Hence, the global AI market for pharma and biotech is expected to reach $4.20 billion by 2027, growing at a <a href="https://www.linkedin.com/pulse/ai-pharma-biotech-market-size-2024-growth-u229e/">30.5% CAGR</a>.
Considering these conducive trends, let's analyze the fundamental aspects of the two <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the second choice.
Stock #2: Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>)
INVA engages in developing and commercializing pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA.
On May 20, 2024, INVA's Specialty Therapeutics and Zai Lab received NMPA approval in China for XACDURO (sulbactam-durlobactam). This drug treats hospital-acquired and ventilator-associated pneumonia caused by resistant Acinetobacter strains. The approval, based on strong clinical data, is a key step in combating antibiotic resistance in the region.
On May 4, 2024, INVA secured a $35 million credit deal with Armata Pharmaceuticals. The funds will support clinical trials for phage-based therapies targeting Pseudomonas aeruginosa and Staphylococcus aureus infections. This collaboration aims to develop new treatments for antibiotic-resistant infections and enhance the value of INVA's partnership with Armata.
In terms of the trailing-12-month gross profit margin, INVA's 86.74% is 52.7% higher than the 56.82% industry average. Likewise, its 43.95% trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin is significantly higher than the 1.88% industry average. Additionally, its 41.61% trailing-12-month levered FCF margin is substantially higher than the 1.09% industry average.
INVA's total revenue for the first quarter ended March 31, 2024, rose 1.5% to $77.50 million. The company's net product sales increased 65.7% over the prior-year quarter to $19.08 million. In addition, its net income and comprehensive income, and net income per share, came in at $36.53 million and $0.46, respectively, up 4.8% and 9.5% year-over-year.
Analysts expect INVA's EPS for the quarter ended June 30, 2024, to increase considerably year-over-year to $0.24. Its revenue for the quarter ending September 30, 2024, is expected to grow 5.5% year-over-year to $70.94 million. Over the past nine months, INVA's stock has gained 52.9% to close the last trading session at $18.99.
INVA's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect strong prospects. It has an overall rating of B, translating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its weighting.
It has an A grade for Value and a B for Quality. It is ranked #10 out of 343 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. Beyond what we stated above, we also have given INVA grades for Growth, Momentum, Stability, and Sentiment. Get all the INVA's ratings <a href="https://stocknews.com/stock/INVA/">here</a>.
Stock #1: Entrada Therapeutics, Inc. (<a href="https://stocknews.com/stock/TRDA/">TRDA</a>) 
TRDA develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs.
In terms of the trailing-12-month EBIT margin, TRDA's 14.57% is 675.5% higher than the 1.88% industry average. Similarly, its 16.56% trailing-12-month EBITDA margin is 174.6% higher than the 6.03% industry average.
TRDA's collaboration revenues for the fiscal first quarter ended March 31, 2024, grew 134% from the year-ago value to $59.12 million. The company's net income was $23.50 million, significantly higher than the net loss of $6.67 million in the prior-year quarter. Additionally, its net income per share was $0.68, compared to a net loss per share of $0.21 in the year-ago quarter.
For the quarter ended June 30, 2024, TRDA's revenue is expected to increase 153.6% year-over-year to $46.08 million.  Over the past three months, the stock has gained 42.6% to close the last trading session at $16.90.
TRDA's POWR Ratings reflect its bright outlook. It has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has a B grade for Value, Sentiment, and Quality. It is ranked #5 in the Biotech industry. To access the additional ratings of TRDA for Growth, Momentum, and Stability, <a href="https://stocknews.com/stock/TRDA/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
INVA shares were trading at $18.94 per share on Wednesday afternoon, down $0.05 (-0.26%). Year-to-date, INVA has gained 18.08%, versus a 16.93% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/inva-trda-2-hot-biotech-stocks-to-watch-this-month/>2 Hot Biotech Stocks to Watch This Month</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

2 Hot Biotech Stocks to Watch This Month

Innoviva GAAP EPS of -$0.55, revenue of $99.9M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Innoviva (NASDAQ:<a href="https://investorplace.com/stock-quotes/inva-stock-quote/">INVA</a>) just reported results for the second quarter of 2024.<ul><li>Innoviva reported earnings per share of -55 cents. This was below the analyst estimate for EPS of 23 cents.</li><li>The company reported revenue of $99.90 million.</li><li>This was 33.75% better than the analyst estimate for revenue of $74.69 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/07/inva-stock-earnings-innoviva-for-q2-of-2024/">INVA Stock Earnings: Innoviva Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

INVA Stock Earnings: Innoviva Misses EPS, Beats Revenue for Q2 2024

IVV: S&P 500 Dashboard For August

IXJ: Healthcare Sector Dashboard For August

Innoviva's Rollercoaster: Critical Care Bets With Respiratory Backing

IHF: Healthcare Dashboard For September

ABBV

ALKS

AMGN

ARMP

BLDR

COLL

EXEL

FHLC

GEHC

HRMY

IDCC

RSPH

SKYW

TRDA

VEEV

VOYA

Press Releases

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Innoviva to Participate in the BofA Securities Health Care Conference

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Innoviva

News

Latest news for Innoviva (NASDAQ:INVA) Stock

People Also Watch